306 related articles for article (PubMed ID: 35148413)
1. Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.
Liu T; Zhu C; Chen X; Guan G; Zou C; Shen S; Wu J; Wang Y; Lin Z; Chen L; Cheng P; Cheng W; Wu A
Neuro Oncol; 2022 Jul; 24(7):1113-1125. PubMed ID: 35148413
[TBL] [Abstract][Full Text] [Related]
2. Injectable microenvironment-responsive hydrogels with redox-activatable supramolecular prodrugs mediate ferroptosis-immunotherapy for postoperative tumor treatment.
Cheng Z; Xue C; Liu M; Cheng Z; Tian G; Li M; Xue R; Yao X; Zhang Y; Luo Z
Acta Biomater; 2023 Oct; 169():289-305. PubMed ID: 37544392
[TBL] [Abstract][Full Text] [Related]
3. SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma.
Han L; Zhou J; Li L; Wu X; Shi Y; Cui W; Zhang S; Hu Q; Wang J; Bai H; Liu H; Guo C; Cao H; Chao M; Hu Y; Mou Y; Jiao Y; Feng D; Wang L; Qu Y
Cell Death Dis; 2022 Dec; 13(12):1071. PubMed ID: 36566214
[TBL] [Abstract][Full Text] [Related]
4. An ultrasound-activated nanoplatform remodels tumor microenvironment through diverse cell death induction for improved immunotherapy.
Ma J; Yuan H; Zhang J; Sun X; Yi L; Li W; Li Z; Fu C; Zheng L; Xu X; Wang X; Wang F; Yin D; Yuan J; Xu C; Li Z; Peng X; Wang J
J Control Release; 2024 Jun; 370():501-515. PubMed ID: 38703950
[TBL] [Abstract][Full Text] [Related]
5. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
[TBL] [Abstract][Full Text] [Related]
6. Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow-Derived Macrophages.
Wu M; Wu L; Wu W; Zhu M; Li J; Wang Z; Li J; Ding R; Liang Y; Li L; Zhang T; Huang B; Cai Y; Li K; Li L; Zhang R; Hu B; Lin F; Wang X; Zheng S; Chen J; You Y; Jiang T; Zhang J; Chen H; Wang Q
Cancer Res; 2023 Mar; 83(5):771-785. PubMed ID: 36622331
[TBL] [Abstract][Full Text] [Related]
7. Biomimetic inducer enabled dual ferroptosis of tumor and M2-type macrophages for enhanced tumor immunotherapy.
Chen M; Shen Y; Pu Y; Zhou B; Bing J; Ge M; Zhu Y; Gao S; Wu W; Zhou M; Shi J
Biomaterials; 2023 Dec; 303():122386. PubMed ID: 37977008
[TBL] [Abstract][Full Text] [Related]
8. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
9. A nanoformulation for immunosuppression reversal and broad-spectrum self-amplifying antitumor ferroptosis-immunotherapy.
Yang Q; Liu T; Zheng H; Zhou Z; Huang Y; Jia H; Fu S; Zhang X; Zhang H; Liu Y; Chen X; Shan W
Biomaterials; 2023 Jan; 292():121936. PubMed ID: 36502663
[TBL] [Abstract][Full Text] [Related]
10. Ferritin light chain promotes the reprogramming of glioma immune microenvironment and facilitates glioma progression.
Li H; Yang C; Wei Y; Li X; Jiang W; Xu Y; Li L; Guo R; Chen D; Gao P; Zhang H; Qin H; Zhang Z; Liu X; Yan D
Theranostics; 2023; 13(11):3794-3813. PubMed ID: 37441589
[No Abstract] [Full Text] [Related]
11. Lighting a Fire: Gasdermin-Mediated Pyroptosis Remodels the Glioma Microenvironment and Promotes Immune Checkpoint Blockade Response.
Cai Y; Li K; Lin J; Liang X; Xu W; Zhan Z; Xue S; Zeng Y; Chai P; Mao Y; Song Z; Han L; Song Y; Zhang X; Wang H
Front Immunol; 2022; 13():910490. PubMed ID: 35784306
[TBL] [Abstract][Full Text] [Related]
12. The Current Landscape of Immune Checkpoint Blockade in Glioblastoma.
Akintola OO; Reardon DA
Neurosurg Clin N Am; 2021 Apr; 32(2):235-248. PubMed ID: 33781505
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
[TBL] [Abstract][Full Text] [Related]
14. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
16. Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas.
Zhang H; Bi Y; Wei Y; Liu J; Kuerban K; Ye L
Mol Cancer Ther; 2021 Jul; 20(7):1305-1315. PubMed ID: 34001635
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk of three novel types of programmed cell death defines distinct microenvironment characterization and pharmacogenomic landscape in breast cancer.
Xu L
Front Immunol; 2022; 13():942765. PubMed ID: 36032140
[TBL] [Abstract][Full Text] [Related]
19. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.
Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F
Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic cell death related risk model to delineate ferroptosis pathway and predict immunotherapy response of patients with GBM.
Feng S; Liang X; Li J; Wang Z; Zhang H; Dai Z; Luo P; Liu Z; Zhang J; Xiao X; Cheng Q
Front Immunol; 2022; 13():992855. PubMed ID: 36248827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
